Pevonedistat
Therapy-Related Acute Myeloid Leukemia
University of Southern CaliforniaPhase 1/2Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Therapy-Related Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Irradiated Allogeneic Cells Rutgers, The State University of New Jersey | Early Phase 1 | C |
Vyxeos Jazz Pharmaceuticals | D |
Same molecule, other indications
Pevonedistat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →